Biomedical Supply UK Ltd 31/12/2025 iXBRL

Company registration number: 16206458

Biomedical Supply UK Ltd

Filleted financial statements

31 December 2025

Pearlman Rose

Chartered Accountants & Statutory Auditors

Suite 1, First Floor

Jack Dash House

2 Lawn House Close

London, E14 9YQ

Biomedical Supply UK Ltd

Contents

Directors and other information

Directors responsibilities statement

Statement of financial position

Statement of changes in equity

Notes to the financial statements

Biomedical Supply UK Ltd

Directors and other information


Directors	Mr Ignacio Bermejo García
	Ms Burcu Öztürk	(Appointed 7 August 2026)
	Mr Ashneel Narayan
	Mr Francisco Jiménez Sirvent	(Resigned 14 May 2026)


Company number	16206458


Registered office	19 The Circle
	Queen Elizabeth Street
	London
	England
	SE1 2JE


Auditor	Pearlman Rose
	Chartered Accountants & Statutory Auditors
	Suite 1, First Floor
	Jack Dash House
	2 Lawn House Close
	London
	E14 9YQ


Accountants	Tax & Advise Ltd
	19 The Circle
	Queen Elizabeth Street
	London
	SE1 2JE

London

Biomedical Supply UK Ltd

Directors responsibilities statement

Year ended 31 December 2025

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;

- make judgments and accounting estimates that are reasonable and prudent; and

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Biomedical Supply UK Ltd

Statement of financial position

31 December 2025

		2025
	Note	£	£

Fixed assets
Intangible assets	5	15,320
Tangible assets	6	15,502
		_______
			30,822

Current assets
Stocks		437,234
Debtors	7	590,017
Cash at bank and in hand		636,080
		_______
		1,663,331
Creditors: amounts falling due
within one year	8	( 1,392,948)
		_______
Net current assets			270,383
			_______
Total assets less current liabilities			301,205

			_______
Net assets			301,205
			_______

Capital and reserves
Called up share capital			1,000
Profit and loss account			300,205
			_______
Shareholders funds			301,205
			_______

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 15 September 2026 , and are signed on behalf of the board by:

Mr Ignacio Bermejo García

Director

Company registration number: 16206458

Biomedical Supply UK Ltd

Statement of changes in equity

Year ended 31 December 2025

	Called up share capital	Profit and loss account	Total
	£	£	£


At 1 January 2025	-	-	-

Profit for the year		300,205	300,205
	_______	_______	_______
Total comprehensive income for the year	-	300,205	300,205

Issue of shares	1,000		1,000
	_______	_______	_______
Total investments by and distributions to owners	1,000	-	1,000

	_______	_______	_______
At 31 December 2025	1,000	300,205	301,205
	_______	_______	_______

Biomedical Supply UK Ltd

Notes to the financial statements

Year ended 31 December 2025

1. General information

The company is a private company limited by shares, registered in England & Wales. The address of the registered office is 19 The Circle, Queen Elizabeth Street, London, England, SE1 2JE.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Foreign currencies

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to profit or loss.

Intangible assets

Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at a revalued amount, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses. Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:


Software	-	33 %	straight line

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Tangible assets

tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 1

5. Intangible assets

	Software	Total
	£	£
Cost
At 1 January 2025	-	-
Additions	20,022	20,022
	_______	_______
At 31 December 2025	20,022	20,022
	_______	_______
Amortisation
At 1 January 2025	-	-
Charge for the year	4,702	4,702
	_______	_______
At 31 December 2025	4,702	4,702
	_______	_______
Carrying amount
At 31 December 2025	15,320	15,320
	_______	_______

6. Tangible assets

	Plant and machinery	Total
	£	£
Cost
At 1 January 2025	-	-
Additions	15,677	15,677
	_______	_______
At 31 December 2025	15,677	15,677
	_______	_______
Depreciation
At 1 January 2025	-	-
Charge for the year	175	175
	_______	_______
At 31 December 2025	175	175
	_______	_______
Carrying amount
At 31 December 2025	15,502	15,502
	_______	_______

7. Debtors

			2025
			£
	Trade debtors		462,237
	Other debtors		127,780
			_______
			590,017
			_______

8. Creditors: amounts falling due within one year

			2025
			£
	Trade creditors		4,860
	Corporation tax		111,414
	Social security and other taxes		45,977
	Other creditors		1,230,697
			_______
			1,392,948
			_______

9. Summary audit opinion

The auditor's report dated 15 September 2026 was unqualified.

The senior statutory auditor was Mohammad Jilani for and on behalf of Pearlman Rose

10. Related party transactions

During the period, the company secured funding of £800,000 from its immediate parent company, Biomedical Supply S.L., to support its ongoing cash flow requirements. At the year end the balance outstanding was £701,132 which is included in note 8 above.

11. Controlling party

The company's immediate and ultimate parent undertaking is Biomedical Supply S.L., a company incorporated in Spain.The ultimate controlling party is Biomedical Supply S.L. by virtue of its ownership of 100% of the issued share capital of the company.